GlassScriptPhysician profile
Olga Katz
NPI 1992858096
$3,243.69
in general payments reported to CMS, 2019-2025
21 companies · $883 in 2025
The $883 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $65.39 · 2021: $100 · 2022: $269 · 2023: $642 · 2024: $501 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.70 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $368.98 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $248.10 | 2019-2024 | Ajovy |
| Otsuka America Pharmaceutical, INC. | $246.55 | 2019-2025 | Rexulti |
| Lundbeck LLC | $242.46 | 2019-2024 | Abilify Maintena, Brintellix, Rexulti |
| Axsome Therapeutics, INC. | $158.07 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $129.05 | 2019-2023 | Trintellix |
| Alkermes, INC. | $112.52 | 2019-2025 | Lybalvi |
| Neurocrine Biosciences, INC. | $92.80 | 2019-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $90.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $87.76 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.93 | 2023-2024 | Caplyta |
| Emd Serono, INC. | $56.14 | 2019 | |
| Bausch Health US, LLC | $54.15 | 2019-2025 | Aplenzin |
| Biogen, INC. | $47.48 | 2025 | Zurzuvae |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.09 | 2019 | |
| Vanda Pharmaceuticals INC. | $38.54 | 2019 | |
| Neuronetics, INC. | $24.33 | 2024 | Neurostar Tms Therapy System |
| Sk Life Science, INC. | $21.02 | 2023 | |
| Shire North American Group INC | $20.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.